BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen N.A., Inc. reported that U101 did not meet the primary endpoint in a Phase 2 clinical study in Chronic Pelvic Pain of bladder origin. However, the Company believes the trial provided the information necessary to proceed with development of the product.
